Gedea´s ambition is to develop the first antibiotic-free treatment that both treats and prevents bacterial vaginosis. pHyph is a vaginal tablet that has shown an excellent medical effect.
pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.
Bacterial vaginosis is a recurring problem that affects women around the world.
In our most recently concluded trial, 90% of patients had a symptom reduction. At day 35 throughout the 4 month follow-up period, recurrence was substantially lower after treatment with pHyph compared to the antibiotic rescue-treated patients.
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis
Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections
Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch
Gedea Biotech initiates EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.